HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arnold won’t be back

This article was originally published in The Tan Sheet

Executive Summary

California Gov. Arnold Schwarzenegger (R) has relinquished his title as executive editor and is foregoing his salary for Flex and Muscle & Fitness magazines, his office announces July 15. His role presents a conflict of interest because the publications receive ad revenue from dietary supplement firms, the state's Democratic Party maintained in charges filed publicly with the Fair Political Practices Commission June 19. Schwarzenegger vetoed a 2004 bill by state Sen. Jackie Speier (D) that would have required the state health department create a list of banned supplements (1"The Tan Sheet" Oct. 18, 2004, p. 18)...

You may also be interested in...

Arnold Says “Hasta La Vista, Baby” To Health Department Supplement List

California schools will not be barred from accepting scholarships from companies that manufacture dietary supplements, following Governor Arnold Schwarzenegger's veto of a bill that would have authorized the state health department to create a list of banned supplements

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts